Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 18/20 | 0.73 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.73 |
| ▸ | PDE4A | P27815 | 9/20 | 0.73 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13350268 | 0.96 | PDE4D (0.67) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL15920428 | 0.88 | PDE4D (0.71) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL24530806 | 0.88 | PDE4D (0.71) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30513591 | 0.87 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL7359780 | 0.87 | PDE4B (0.76) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL28607507 | 0.87 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL19158 | 0.84 | PDE4B (1.00) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29349467 | 0.84 | PDE4B (1.00) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL2887750 | 0.84 | PDE4B (0.92) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30084829 | 0.84 | PDE4B (0.92) | PDE4DPDE4BPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618142-B2 | Process for the preparation of roflumilast | TAKEDA GMBH (DE) | 2013-12-31 | — | — | US | claimed |
| US-8604064-B2 | Process for the preparation of roflumilast | TAKEDA GMBH (DE) | 2013-12-10 | — | — | US | claimed |
| US-8536206-B2 | Process for the preparation of roflumilast | TAKEDA GMBH (DE) | 2013-09-17 | — | — | US | claimed |
| US-20130231374-A1 | Novel Process For The Preparation Of Roflumilast | NYCOMED GMBH (DE) | 2013-09-05 | — | — | US | claimed |
| US-20130224299-A1 | Novel Process For The Preparation Of Roflumilast | NYCOMED GMBH (DE) | 2013-08-29 | — | — | US | claimed |
| US-20120294942-A1 | NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST | NYCOMED GMBH (DE) | 2012-11-22 | — | — | US | claimed |
| US-20060004061-A1 | Novel process for the preparation of roflumilast | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | claimed |
| CN-103613532-A | Preparation method of roflumilast related substance C | JIANGSU AVENTIS PHARMACEUTICAL CO LTD | 2014-03-05 | — | — | CN | disclosed |
| US-8618142-B2 | Process for the preparation of roflumilast | TAKEDA GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-8618142-B2 | Process for the preparation of roflumilast | TAKEDA GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-8604064-B2 | Process for the preparation of roflumilast | TAKEDA GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-8604064-B2 | Process for the preparation of roflumilast | TAKEDA GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-8536206-B2 | Process for the preparation of roflumilast | TAKEDA GMBH (DE) | 2013-09-17 | — | — | US | disclosed |
| EP-2193808-A1 | Synergistic combination | Nycomed GmbH (DE) | 2010-06-09 | — | — | EP | disclosed |
| EP-1606261-B1 | NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST | NYCOMED GMBH (DE) | 2009-11-04 | — | — | EP | disclosed |
| US-20090171096-A1 | Novel process for the preparation of roflumilast | NYCOMED GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-7470791-B2 | Process for the preparation of roflumilast | NYCOMED GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20060004061-A1 | Novel process for the preparation of roflumilast | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | disclosed |
| EP-1606261-A1 | NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST | ALTANA Pharma AG (DE) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080967-A1 | NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST | ALTANA PHARMA AG (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004061-A1 | Novel process for the preparation of roflumilast | PLAT, VASP, F2R | PDE4D 27/4885PDE4B 22/4885PDE4A 18/4885 |
| US-20130231374-A1 | Novel Process For The Preparation Of Roflumilast | CMA1, PLAT, REN | PDE4D 19/4885PDE4B 13/4885PDE4A 14/4885 |
| US-20120294942-A1 | NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST | PLAT, VASP, F2R | PDE4D 27/4885PDE4B 22/4885PDE4A 18/4885 |
| US-20130224299-A1 | Novel Process For The Preparation Of Roflumilast | CMA1, CPA3, PLAT | PDE4D 45/4885PDE4B 18/4885PDE4A 21/4885 |
| US-20090171096-A1 | Novel process for the preparation of roflumilast | PLAT, VASP, F2R | PDE4D 27/4885PDE4B 22/4885PDE4A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.